Whalesbook
Modi Lifecare Faces Insolvency Over Royalty Debt
The National Company Law Appellate Tribunal (NCLAT) has revived Lyka Labs' insolvency plea against Modi Lifecare Industries, ordering the company to pay Rs 63 lakh in royalty debt. This ruling reverses an earlier decision by the National Company Law Tribunal (NCLT) and puts Modi Lifecare under significant financial pressure.
The debt stems from a technical guidance agreement signed in September 2012, which involved royalties for product labels and cartons. Lyka Labs claims Modi Lifecare acknowledged the dues, stating the payment was not dependent on sales figures. Modi Lifecare's defense, which cited a prior dispute, was rejected by the NCLAT. The tribunal noted correspondence as proof of acknowledgment and ruled that the lack of formal invoices did not nullify Lyka Labs' claim.
Modi Lifecare Industries has 30 days to pay the Rs 63 lakh to Lyka Labs. Failure to do so will prompt the NCLT to begin insolvency proceedings against the Ahmedabad-based pharmaceutical company. This decision is a major win for Lyka Labs, which had its initial plea dismissed by the NCLT before successfully appealing. The NCLAT's findings weaken Modi Lifecare's legal position and highlight its financial strain, especially when compared to larger competitors like Dr. Reddy's Laboratories and Sun Pharmaceutical Industries.
Modi Lifecare's future now depends on its ability to meet this payment deadline. If it fails, a complex insolvency process could begin, potentially affecting its operations and market standing. This situation underscores the importance of adhering to contractual obligations and making timely financial settlements.